Eli Lilly Seals $1.9 Billion Ascidian Tie-Up, Bolsters Genetic Therapy Pipeline
LLY•Eli Lilly committed up to $1.9 billion to partner with Ascidian Therapeutics on RNA exon editing-based kidney disease therapies, leading clinical, manufacturing and commercialization after Ascidian’s discovery work. It’s the company’s third deal this week, following $1.26 billion Hanmi Pharm and $3 billion Haisco agreements, while three acquisitions diversify away from weight-loss reliance.
1. Ascidian Partnership Details
Eli Lilly has agreed to invest up to $1.9 billion in a collaboration with Ascidian Therapeutics to discover and develop RNA exon editing therapies for monogenic kidney diseases. Under the deal, Ascidian leads target discovery and early preclinical work, while Lilly advances additional preclinical activities, clinical R&D, manufacturing and commercialization.
2. Lilly’s Recent Deal Spree
This partnership marks Lilly’s third major agreement in a single week, following a $1.26 billion licensing arrangement with Hanmi Pharm for a GLP-2 agonist and a $3 billion deal with Haisco Pharmaceutical to co-develop innovative medicines. The flurry of deals underscores Lilly’s strategic push into genetic medicines and innovative therapeutic modalities.
3. Pipeline Diversification Moves
Beyond collaborations, Lilly has completed three acquisitions aimed at reducing its dependence on its core weight-loss drug portfolio. These transactions expand its therapeutic scope into new areas and diversify revenue streams, complementing its growing genetic medicines pipeline.
